Download PDF
J Neurol Surg B Skull Base
DOI: 10.1055/a-2531-2446
Original Article

Exploring the Role of Intraoperative Prolactin Levels in Surgical Management of Prolactinomas: Predicting Operative Success and Enhancing Surgical Decision-Making

Salomon Cohen-Cohen 
1   Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
Giorgos Michalopoulos
1   Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
Irina Bancos
2   Department of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, United States
,
Lucinda M. Gruber
2   Department of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, United States
,
Carlos D. Pinheiro Neto
3   Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
Jamie J. Van Gompel 
1   Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, United States
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective Prolactinomas comprise half of all pituitary adenomas. This study explores the significance of measuring intraoperative (IO) prolactin (PRL) levels in guiding surgical decision-making and predicting operative success.

Methods Retrospective cohort study design of consecutive patients with prolactinomas who underwent transsphenoidal resection from June 2021 to May 2023. IO PRL was measured after tumor resection was completed. Remission was defined as normalization of PRL levels during follow-up without medication. Outcomes included factors associated with remission, utilizing significance thresholds at p < 0.05.

Results Thirteen patients were included with a 5.3-month median follow-up (range, 3–15 months). Most of the tumors were microadenomas (61%), with a median preoperative PRL level of 116 ng/mL (range, 25–471). Gross total resection was achieved in 69% of patients, all of whom attained remission. The median IO PRL was 19.8 ng/mL (range, 1–329), the postoperative day 1 PRL of 3.6 ng/mL (range, 1–203), and the latest PRL at 9.3 ng/mL (range, 1–137). A ≥40% decline in IO PRL from baseline was identified as the optimal cutoff for predicting biochemical remission, with 89% sensitivity, 75% specificity, and 85% accuracy.

Conclusion Monitoring PRL levels intraoperatively may be a useful biomarker aiding surgeon's assessment of the extent of tumor resection and guide surgical decision-making. Further refinement of the immunoassay assay and clinical testing with more extensive prospective studies are needed.

Keywords

prolactinomas - prolactin - intraoperative - endoscopic - transsphenoidal


Publication History

Received: 07 November 2024

Accepted: 31 January 2025

Accepted Manuscript online:
04 February 2025

Article published online:
24 February 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Albright SV, McCart JA, Libutti SK. et al. Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma. Ann Clin Biochem 2002; 39 (Pt 5): 513-515
    CrossrefPubMedSearch in Google Scholar
  • 2 Proye C, Pattou F, Carnaille B, Lefebvre J, Decoulx M, d'Herbomez M. Intraoperative insulin measurement during surgical management of insulinomas. World J Surg 1998; 22 (12) 1218-1224
    CrossrefPubMedSearch in Google Scholar
  • 3 Graham KE, Samuels MH, Raff H, Barnwell SL, Cook DM. Intraoperative adrenocorticotropin levels during transsphenoidal surgery for Cushing's disease do not predict cure. J Clin Endocrinol Metab 1997; 82 (06) 1776-1779
    PubMedSearch in Google Scholar
  • 4 Woods JJ, Sampson ML, Ruddel ME, Remaley AT. Rapid intraoperative cortisol assay: design and utility for localizing adrenal tumors by venous sampling. Clin Biochem 2000; 33 (06) 501-503
    CrossrefPubMedSearch in Google Scholar
  • 5 Nussbaum SR, Thompson AR, Hutcheson KA, Gaz RD, Wang CA. Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism. Surgery 1988; 104 (06) 1121-1127
    PubMedSearch in Google Scholar
  • 6 Garner SC, Leight Jr GS. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery 1999; 126 (06) 1132-1137 , discussion 1137–1138
    CrossrefPubMedSearch in Google Scholar
  • 7 Patel KN, Caso R. Intraoperative parathyroid hormone monitoring: optimal utilization. Surg Oncol Clin N Am 2016; 25 (01) 91-101
    CrossrefPubMedSearch in Google Scholar
  • 8 Czirják S, Bezzegh A, Gál A, Rácz K. Intra- and postoperative plasma ACTH concentrations in patients with Cushing's disease cured by transsphenoidal pituitary surgery. Acta Neurochir (Wien) 2002; 144 (10) 971-977 , discussion 977
    CrossrefPubMedSearch in Google Scholar
  • 9 Zachariah MA, Cua S, Muhlestein WE. et al. Intraoperative predictor of remission in Cushing disease. Oper Neurosurg (Hagerstown) 2023; 24 (04) 460-467
    CrossrefPubMedSearch in Google Scholar
  • 10 Valdemarsson S, Ljunggren S, Cervin A. et al. Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement?. Scand J Clin Lab Invest 2001; 61 (06) 459-470
    CrossrefPubMedSearch in Google Scholar
  • 11 van den Berg G, van Dulken H, Frölich M, Meinders AE, Roelfsema F. Can intra-operative GH measurement in acromegalic subjects predict completeness of surgery?. Clin Endocrinol (Oxf) 1998; 49 (01) 45-51
    CrossrefPubMedSearch in Google Scholar
  • 12 Yano S, Shinojima N, Kawashima J, Kondo T, Hide T. Intraoperative scoring system to predict postoperative remission in endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. World Neurosurg 2017; 105: 375-385
    CrossrefPubMedSearch in Google Scholar
  • 13 Zachariah MA, Bozer JJ, Cua S. et al. Intraoperative prediction of long-term remission in acromegaly. Oper Neurosurg (Hagerstown) 2023; 24 (01) 74-79
    CrossrefPubMedSearch in Google Scholar
  • 14 Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 2019; 33 (02) 101290
    CrossrefPubMedSearch in Google Scholar
  • 15 Giraldi EA, Ioachimescu AG. The role of dopamine agonists in pituitary adenomas. Endocrinol Metab Clin North Am 2020; 49 (03) 453-474
    CrossrefPubMedSearch in Google Scholar
  • 16 Steeds RP, Stiles CE, Sharma V, Chambers JB, Lloyd G, Drake W. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Echo Res Pract 2019; 6 (01) G1-G8
    CrossrefPubMedSearch in Google Scholar
  • 17 Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 2019; 180 (01) 31-40
    CrossrefPubMedSearch in Google Scholar
  • 18 Souteiro P, Belo S, Carvalho D. Dopamine agonists in prolactinomas: when to withdraw?. Pituitary 2020; 23 (01) 38-44
    CrossrefPubMedSearch in Google Scholar
  • 19 Giese S, Nasi-Kordhishti I, Honegger J. Outcomes of transsphenoidal microsurgery for prolactinomas - a contemporary series of 162 cases. Exp Clin Endocrinol Diabetes 2021; 129 (03) 163-171
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Yagnik KJ, Erickson D, Bancos I. et al. Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 2021; 24 (06) 978-988
    CrossrefPubMedSearch in Google Scholar
  • 21 Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F. et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. a systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105 (03) e32-e41
    CrossrefPubMedSearch in Google Scholar
  • 22 Wright K, Chaker L, Pacione D. et al. Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg 2021; 154: e349-e369
    CrossrefPubMedSearch in Google Scholar
  • 23 Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus 2004; 16 (04) E2
    CrossrefPubMedSearch in Google Scholar
  • 24 Donegan D, Atkinson JL, Jentoft M. et al. Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 2017; 23 (01) 37-45
    CrossrefPubMedSearch in Google Scholar
  • 25 Micko AS, Wöhrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015; 122 (04) 803-811
    CrossrefPubMedSearch in Google Scholar
  • 26 R Core Team. A language and environment for statistical computing. 2013. R Foundation for Statistical Computing; Vienna, Austria: 2018
    Search in Google Scholar
  • 27 Heinzen E, Sinnwell J, Atkinson E. et al. Arsenal: an arsenal of 'R' functions for large-scale statistical summaries. R Package Version 2021;3(02):
    PubMed
  • 28 Thiele C, Hirschfeld G. cutpointr: improved estimation and validation of optimal cutpoints in R. arXiv preprint arXiv:200209209. 2020
    PubMed
  • 29 Hadley W. Ggplot2: Elegrant graphics for data analysis. Springer; 2016
    Search in Google Scholar
  • 30 Chang EF, Sughrue ME, Zada G, Wilson CB, Blevins Jr LS, Kunwar S. Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas. Pituitary 2010; 13 (03) 223-229
    CrossrefPubMedSearch in Google Scholar
  • 31 Menucci M, Quiñones-Hinojosa A, Burger P, Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 2011; 14 (01) 68-74
    CrossrefPubMedSearch in Google Scholar
  • 32 Chen Z, Shou X, Ji L. et al. Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases. J Clin Endocrinol Metab 2024; 109 (06) 1433-1442
    CrossrefPubMedSearch in Google Scholar
  • 33 Hlaváč M, Knoll A, Mayer B. et al. Ten years' experience with intraoperative MRI-assisted transsphenoidal pituitary surgery. Neurosurg Focus 2020; 48 (06) E14
    CrossrefPubMedSearch in Google Scholar
  • 34 Buchfelder M, Schlaffer SM. Intraoperative magnetic resonance imaging during surgery for pituitary adenomas: pros and cons. Endocrine 2012; 42 (03) 483-495
    CrossrefPubMedSearch in Google Scholar
  • 35 Juthani RG, Reiner AS, Patel AR. et al. Radiographic and clinical outcomes using intraoperative magnetic resonance imaging for transsphenoidal resection of pituitary adenomas. J Neurosurg 2020; 134 (06) 1824-1835
    CrossrefPubMedSearch in Google Scholar
  • 36 Lakomkin N, Van Gompel JJ, Post KD, Cho SS, Lee JYK, Hadjipanayis CG. Fluorescence guided surgery for pituitary adenomas. J Neurooncol 2021; 151 (03) 403-413
    CrossrefPubMedSearch in Google Scholar
  • 37 Turkington RW. Secretion of prolactin by patients with pituitary and hypothalamic tumors. J Clin Endocrinol Metab 1972; 34 (01) 159-164
    CrossrefPubMedSearch in Google Scholar
  • 38 Chen LS, Singh RJ. Niche point-of-care endocrine testing - reviews of intraoperative parathyroid hormone and cortisol monitoring. Crit Rev Clin Lab Sci 2018; 55 (02) 115-128
    CrossrefPubMedSearch in Google Scholar
  • 39 Lee GY, Kim SH, Kim EH. Role of immediate postoperative prolactin measurement in female prolactinoma patients: predicting long-term remission after complete tumor removal. Brain Tumor Res Treat 2023; 11 (03) 204-209
    CrossrefPubMedSearch in Google Scholar
  • 40 Amar AP, Couldwell WT, Chen JC, Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002; 97 (02) 307-314
    CrossrefPubMedSearch in Google Scholar